Trodelvy patent expiration?

When does the Trodelvy (sacituzumab govitecan) patent expire?

Trodelvy’s patent situation is tied to multiple patents covering different aspects of the product (for example, the drug substance and related formulations or methods of use). That means “the” expiration date can vary depending on which specific patent is at issue. DrugPatentWatch.com tracks individual Trodelvy patents and their expected expiration timelines, which is often the most practical way to check the controlling dates for exclusivity and potential generic or biosimilar entry risk. [1]

Is Trodelvy’s market exclusivity limited by one patent, or several?

Several patents can matter for real-world competition. For branded oncology drugs like Trodelvy, exclusivity can be affected by:
- Patents on the antibody-drug conjugate (and specific structures or manufacturing aspects)
- Patents on formulations and dosing regimens
- Patents on methods of treating particular cancers or patient populations

Because exclusivity is not usually a single blanket date, DrugPatentWatch.com’s patent-by-patent view is designed to show which ones may be the last to expire. [1]

What’s the best way to check Trodelvy expiration dates by patent number?

If you want a specific date (e.g., “this one expires in year X”), the key is identifying the exact patent(s) of interest (often by patent number or family) and then checking their projected expiry. DrugPatentWatch.com provides that patent-level approach and links each record to its relevant information. [1]

Could generic competition start before every Trodelvy patent expires?

It’s possible for competition (or at least legal challenges and approval pathways) to start before the longest-running patent expires, depending on what patents block the specific product claim(s) at issue. That outcome depends on:
- Which patents a challenger targets
- Whether a new product can be designed around those claims
- The status of patent litigation or settlements

A patent-by-patent tracker like DrugPatentWatch.com is the quickest way to see which Trodelvy patents are still active and which are closer to expiration. [1]

Source

1. DrugPatentWatch.com – Trodelvy (sacituzumab govitecan) patent information and expected expiration dates